Momelotinib

Momelotinib is a kinase inhibitor targeted drug that was approved by the US FDA for the first time in 2023, providing a new treatment option for adult patients with anemia

1. Drug name

1. Generic name : Momelotinib

2. Trade name :OJJAARA

2. Indications

U200c is used to treat adult anemia patients with moderate-to-high-risk myelofibrosis (MF), including primary MF or secondary MF (post-polycythemia vera and post-essential thrombocythemia).

3. Specifications and properties of

1. Specifications of :100mg.

2. Characteristics : Film-coated tablets.

IV. Main ingredient

Active ingredient : Momelotinib dihydrochloride monohydrate (see attachment for chemical name).

5. Usage and dosage

1. Recommended dosage of : 200mg orally, once a day, can be taken before or after meals.

2. Swallow whole tablet and do not cut, chew or crush it.

3. What to do if you miss a dose of : If you miss a dose, take it as originally planned the next day, and there is no need to take another dose.

VI. Dose adjustment

1. Hepatic insufficiency :

Severe liver damage (Child-Pugh C grade): The starting dose is reduced to 150 mg/day.

2. Adjust for adverse reactions (need to be based on platelets, neutrophils and other indicators):

In case of thrombocytopenia or neutropenia, the dose needs to be interrupted or reduced (see the attached table for details).

7. Medication precautions

1. Influence of diet : is not affected by food.

2. Vomiting treatment : If you vomit after taking the medicine, there is no need to take a supplementary dose. Take the medicine the next day as planned.

3. Monitoring requirements :

Blood routine and liver function must be tested regularly before and during medication.

Be alert to symptoms such as infection, bleeding, and blood clots.

8. Medication for special groups

1. Pregnant women : may cause fetal damage and should only be used when the benefits outweigh the risks.

2. Lactation : Breastfeeding is prohibited for at least 1 week after stopping the drug.

3. Elderly : No need to adjust the dose.

9. Adverse reactions

1. Common (≥20%) : Thrombocytopenia, bleeding, bacterial infection, fatigue, dizziness, diarrhea, nausea.

2. Serious risks : Infection, liver toxicity, cardiovascular events, malignant tumors (especially for smokers).

10. Contraindications

There are no absolute contraindications to , but patients with active infection need to delay medication.

11. Drug interactions

1. OATP1B1/B3 inhibitor (such as rifampicin): May increase molotinib exposure, and adverse reactions need to be monitored.

2. BCRP substrate (such as rosuvastatin): The dosage needs to be adjusted (rosuvastatin limit is 5-10mg/day).

12. Storage method

It is not clearly stated. It is recommended to store conventional oral drugs (avoid light, dry, below 25℃).